SEC Form 4 · accession 0000874015-17-000016
IONIS PHARMACEUTICALS INC · IONS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brett P Monia
Officer — SVP, Antisense Drug Discovery
Period of report
Jan 15, 2017
Accepted (ET)
Jan 18, 2017 · 6:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874015
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 15, 2017 | M | 1,415 | $0.00 | A | 9,287 | D | |
| Common StockF2 | Jan 17, 2017 | S | 553 | $46.29 | D | 8,734 | D | |
| Common StockF3 | Jan 15, 2017 | M | 1,875 | $0.00 | A | 10,609 | D | |
| Common StockF4 | Jan 17, 2017 | S | 733 | $46.291 | D | 9,876 | D | |
| Common StockF5 | Jan 15, 2017 | M | 1,518 | $0.00 | A | 11,394 | D | |
| Common StockF6 | Jan 17, 2017 | S | 593 | $46.291 | D | 10,801 | D | |
| Common StockF7 | Jan 15, 2017 | M | 1,594 | $0.00 | A | 12,395 | D | |
| Common StockF8 | Jan 17, 2017 | S | 623 | $46.29 | D | 11,772 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF9,F10 | — | Jan 15, 2017 | A | 8,000 | A | — | — | Common Stock | 8,000 | 8,000 | D |
| Restricted Stock UnitsF2,F9,F11 | — | Jan 15, 2017 | M | 1,415 | D | — | — | Common Stock | 1,415 | 0 | D |
| Restricted Stock UnitsF4,F9,F11 | — | Jan 15, 2017 | M | 1,875 | D | — | — | Common Stock | 1,875 | 1,875 | D |
| Restricted Stock UnitsF6,F9,F11 | — | Jan 15, 2017 | M | 1,518 | D | — | — | Common Stock | 1,518 | 3,034 | D |
| Restricted Stock UnitsF8,F9,F11 | — | Jan 15, 2017 | M | 1,594 | D | — | — | Common Stock | 1,594 | 4,779 | D |
Explanation of responses
- F1Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 30, 2013.
- F10Grant 1/15/2017 to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on January 15, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2021. The RSU is vested as to 0 shares on January 15, 2017.
- F11Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.
- F2The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 30, 2013.
- F3Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2014.
- F4The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2014.
- F5Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2015.
- F6The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2015.
- F7Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2016.
- F8The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2016.
- F9Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.